-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
Elimination of Clinical Trial Disparities Requires a New Lens for Viewing Justice, New Approach to Patient’s Role
By Joy Curzio Although there has been tremendous progress in lung cancer over the past 10 years, with a number of new drug indications being approved in the United States this year alone, disparities in clinical trial participation look very much the same now as they did a decade or two ago. Janet Freeman-Daily, co-founder…
-
Immunotherapy, TKIs for Resectable/Resected NSCLC: Dr. Masahiro Tsuboi Provides a Comprehensive Overview of Promising Phase II Data, Phase III Status
By Jill Daigneault, PhD Surgical outcomes for early-stage NSCLC are still very poor due to the high rate of recurrence through distant metastases. It is likely that these distant metastases are present at initial resection as undetectable micrometastases. In order to target these potential sites of recurrence in early-stage patients, trials using immunotherapy (IO) and…
-
First-line Sintilimab Plus Platinum-Based Chemotherapy Prolongs PFS in Advanced Nonsquamous NSCLC
By Kara Nyberg, PhD Adding sintilimab, an anti-PD-1 antibody, to first-line platinum-based chemotherapy enhances efficacy in patients with locally advanced or metastatic nonsquamous NSCLC. In the randomized, placebo-controlled, phase III ORIENT-11 trial conducted in China, median progression-free survival (PFS) reached 5.0 months with chemotherapy but improved to 8.9 months when sintilimab was paired with chemotherapy…
-
Deeper Dive: A Plethora of Prediction Models
By Annette McWilliams, MBBS, FRACP, MD, FRCPSC In reference to: Nemesure B, Clouston S, Albano D, Kuperberg S, Bilfinger TV. Will that pulmonary nodule become cancerous? A risk prediction model for incident lung cancer. Cancer Prev Res (Phila). 2019;12(7):463-470. Technologic advancements in CT technology during the past 20 years have led to the frequent detection…
-
Lung Cancer Diagnosis and Staging During COVID-19
Re-establishing protocols and systems for accurate and timely diagnosis and staging despite fears and high volume is critical to patient survival.
-
Can We Use the Word ‘Cure’ for a Subset of Selected Patients With Advanced NSCLC?
By Karen L. Reckamp, MD When advanced NSCLC is diagnosed, the word “cure” is avoided; we focus on palliation of symptoms with prolonged survival. Unfortunately, there are more than 200,000 cases of lung cancer estimated for 2020, which will cause more deaths than breast, prostate, colorectal, and brain cancers combined.1 However, recent statistics have demonstrated…
-
Small Steps Forward in SCLC: Is a Giant Leap on the Horizon?
The absence of an OS benefit in more than 3 decades of clinical trials for extensive-stage SCLC (ES-SCLC) had become an all-too-familiar refrain among the introductions to numerous publications and grant applications. However, within the past 2 years, the publication of two landmark studies of immune checkpoint inhibitors (ICIs) in combination with frontline chemotherapy for…
-
Immune Checkpoint Inhibitors Have Led to Substantial Improvements in Lung Cancer but Are Still Not a ‘Cure’
By Edward B. Garon, MD Immune checkpoint inhibitors have dramatically changed the treatment of patients with lung cancer. The degree of efficacy seen with these agents would have been nearly unimaginable a decade ago. We now have long term follow-up data demonstrating that a substantial percentage of patients are alive 5 years or more after…
-
Liquid biopsy for early lung cancer detection and cancer interception
By Christian Rolfo, MD, PhD, MBA, Dr.hc. Over the past several years, three large randomized clinical trials demonstrated that low-dose computed tomography (LDCT) screening is a valuable method for lung cancer screening in high-risk individuals and can significantly reduce lung cancer mortality.1-3 Economic costs, technical and organizational requirements, exposure to not negligible radiation doses, the…
-
The Chen-Huang Center for EGFR-Mutant Lung Cancers Represents a ‘Concentrated and Focused Effort’ in Studying Th is Disease Subset
Posted: August 21, 2020 The Chen-Huang Center for EGFR Mutant Lung Cancers, founded at Dana-Farber Cancer Institute earlier this year, is poised to make advances in the study and treatment of this subset of lung cancer. Funded through a $5 million gift from Winston Chen, PhD, and his wife Phyllis Huang, the Chen-Huang Center is…
View ILCN Archives
Provider Resources
Popular Articles